Stroboscopic light stimulation safety within and beyond laboratory settings: Observational evidence and practical guidance.

Stroboscopic light stimulation (SLS) reliably evokes geometric visual hallucinations and, in some contexts, altered-state experiences. Its increasing use in research, public, recreational and exploratory clinical settings creates a need for proportionate safety guidance. The main concern is a visually triggered seizure in a susceptible individual; reported non-epileptic responses include discomfort or distress. We combined a retrospective survey of safety practices and reported events across four laboratories, provider-reported operational data from two commercial SLS platforms, and a focused review of photosensitivity and sensory intolerance. Laboratory contributors reported 20 non-serious events that interrupted or modified participation, with no reported seizures or syncopal episodes. One commercial provider reported nine medically important or otherwise notable events across approximately 3.8 million sessions. The other reported five such events across more than 400,000 sessions. Because commercial adverse-event capture was passive and the laboratory protocols and monitoring procedures were heterogeneous, these figures cannot be used to estimate incidence or establish screening effectiveness. This synthesis informed a provisional Sussex Strobe Safety Screening Questionnaire (4SQ) and a layered, context-specific risk-management approach. The resulting framework distinguishes non-serious tolerability concerns from the principal medical risk of a visually provoked seizure in a susceptible individual, and supports conservative monitored familiarisation exposure, immediate stopping procedures and systematic adverse-event surveillance. The predictive performance of the 4SQ and the effectiveness of these precautions require formal evaluation; absolute SLS risk remains uncertain.